Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
PALI
Palisade Bio, Inc.
CAPPED RATING
Palisade Bio, Inc. (PALI) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (F).
Quantitative Factor Evaluation • Updated
Overall Rating
1.8
/ 5.0
D+
Value
C
Factor Score
2.2
/ 5.0
Growth
F
Factor Score
0.5
/ 5.0
Profitability
C-
Factor Score
2.0
/ 5.0
Momentum
D+
Factor Score
1.7
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
1.2
EV / EBITDA
-1.8
Rev Growth YoY
N/A
Gross Margin
N/M
Price Return 3M
-47.9%
Price Return 12M
-45.1%
Catalyst Signal
0.00
Market Cap
$201.0M
TTM Revenue
$500.0K
Price / Sales
402.0
ROE
-75.6%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C (2.2) | F (0.5) | C- (2.0) | D+ (1.7) | C+ (2.6) | D+ (1.8) |
| 2026-11-07 | C (2.3) | F (0.6) | C (2.2) | D+ (1.7) | C+ (2.7) | C- (1.9) |
| 2026-10-31 | C (2.3) | F (0.5) | C- (2.1) | D+ (1.5) | C+ (2.7) | D+ (1.8) |
| 2026-10-24 | C- (2.1) | F (0.6) | C- (2.1) | D+ (1.7) | C+ (2.6) | D+ (1.8) |
| 2026-10-17 | C- (2.1) | F (0.5) | C- (2.1) | C- (1.9) | C+ (2.6) | D+ (1.8) |
Page
1
of
4